Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
Antiviral Agents
/ therapeutic use
COVID-19
/ epidemiology
Coronavirus Infections
/ epidemiology
Databases, Factual
Host-Pathogen Interactions
Humans
Immune Evasion
/ immunology
Immunity, Innate
/ immunology
Middle East Respiratory Syndrome Coronavirus
/ drug effects
Severe acute respiratory syndrome-related coronavirus
/ drug effects
SARS-CoV-2
/ drug effects
Severe Acute Respiratory Syndrome
/ epidemiology
Virus Replication
/ drug effects
COVID-19 Drug Treatment
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
03
2021
accepted:
14
09
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction.
Identifiants
pubmed: 34587192
doi: 10.1371/journal.pone.0257965
pii: PONE-D-21-09155
pmc: PMC8480897
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257965Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Virol. 2005 Dec;79(23):14708-18
pubmed: 16282471
JAMA. 2020 Nov 10;324(18):1899-1901
pubmed: 32970139
Immunity. 2020 Aug 18;53(2):248-263
pubmed: 32717182
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
Nat Immunol. 2019 Dec;20(12):1574-1583
pubmed: 31745335
Nat Microbiol. 2019 Jun;4(6):914-924
pubmed: 30936491
Curr Opin Virol. 2015 Oct;14:24-9
pubmed: 26143158
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513
Clin Microbiol Infect. 2020 Jun;26(6):729-734
pubmed: 32234451
J Neurol Sci. 2020 Jul 15;414:116884
pubmed: 32464367
JAMA Cardiol. 2021 Jan 1;6(1):116-118
pubmed: 32915194
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
J Biomol Struct Dyn. 2021 Oct;39(16):6195-6217
pubmed: 32686993
Exp Physiol. 2016 Nov 1;101(11):1327-1337
pubmed: 26969796
Cureus. 2020 Aug 3;12(8):e9540
pubmed: 32905500
Mol Ther Nucleic Acids. 2019 Sep 6;17:10-23
pubmed: 31173947
Br J Haematol. 2020 Jun;189(5):846-847
pubmed: 32304577
Signal Transduct Target Ther. 2020 Sep 14;5(1):201
pubmed: 32929074
Nature. 2021 Jun;594(7862):240-245
pubmed: 33979833
Med Hypotheses. 2020 Apr 22;140:109777
pubmed: 32344314
Genet Med. 2020 Nov;22(11):1874-1882
pubmed: 32601386
Science. 2020 Jul 17;369(6501):256-257
pubmed: 32675364
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Virus Res. 2008 Apr;133(1):101-12
pubmed: 17451827
J Immunol. 2014 Sep 15;193(6):3080-9
pubmed: 25135833
Lancet Infect Dis. 2020 Sep;20(9):996-998
pubmed: 32539989
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Nat Med. 2020 Mar;26(3):317-319
pubmed: 32108160
J Innate Immun. 2018;10(4):315-327
pubmed: 30016790
J Geriatr Cardiol. 2020 Apr;17(4):224-228
pubmed: 32362922
Gut. 2017 Feb;66(2):301-313
pubmed: 26642860
J Intern Med. 2021 Aug;290(2):451-461
pubmed: 33403772
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
Philos Trans A Math Phys Eng Sci. 2016 Apr 13;374(2065):20150202
pubmed: 26953178
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
Diabetes Metab Syndr. 2020 May - Jun;14(3):247-250
pubmed: 32247212
PLoS One. 2013 Oct 14;8(10):e77256
pubmed: 24155933
PLoS Biol. 2020 Sep 8;18(9):e3000849
pubmed: 32898168
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
pubmed: 9843981
Cells. 2019 Aug 27;8(9):
pubmed: 31461880
J Cell Biol. 2012 Jun 25;197(7):857-67
pubmed: 22733998
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
J Immunol. 2004 Dec 1;173(11):6938-48
pubmed: 15557190
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452
pubmed: 32780793
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
BMC Bioinformatics. 2011 Jul 28;12:307
pubmed: 21798031
PLoS One. 2020 Jun 5;15(6):e0234185
pubmed: 32502186
Science. 2020 Jun 26;368(6498):1499-1504
pubmed: 32358203
ACS Pharmacol Transl Sci. 2020 Jun 16;3(4):780-782
pubmed: 32821884
Hum Vaccin Immunother. 2018 Jul 3;14(7):1763-1772
pubmed: 29580160
Biomol Ther (Seoul). 2018 May 1;26(3):242-254
pubmed: 29310427
Immunity. 2015 Mar 17;42(3):406-17
pubmed: 25786173
JAMA. 2020 Oct 6;324(13):1347-1348
pubmed: 32822495
Nat Commun. 2020 Aug 20;11(1):3635
pubmed: 32820175
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9869-E9878
pubmed: 30275324